REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
11/17/2025
Back to search
Official data from USPTO
GEMCITABINE IN 0.9% SODIUM CHLORIDE INJECTION 1,500 MG PER 150 ML (10 MG/ML)
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
37
Latest update
11/18/2025
Trademark type
Combined
Nice classes
5, 10
Filing date
09/20/2018
Registration date
11/17/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/17/2020
Last transaction
11/18/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
07/08/2020
First use in commerce
07/08/2020
Drawing code
3
Owner type
16
Owner location
Mumbai, Maharashtra, IN
Examiner
GANESH,HARINI
Law office
N40
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a pink outline of a rectangle surrounding the word "GEMCITABINE" in black lettering above the words "in 0.9% sodium chloride injection" in black lettering, along with a pink arched curve filling in the lower left hand corner, all of the foregoing above a smaller rectangle filled in pink, with the words "1,500 mg per 150 mL (10 mg/mL)" in white letters. The color white in the rectangle with the arched curve represents background only and is not claimed as a feature of the mark.
Holders and representatives
Holders
Sun Pharmaceutical Industries Limited
Representatives
Craig Kuchii, Esq. SUN PHARMACEUTICAL INDUSTRIES, INC.
Technical classification
Nice Classes
Class 5Class 10
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
medicinal and pharmaceutical preparations packed in ready to use infusion bags for chemotherapyreduction of tension and anxietyimprovement of heart functioncorrection of hemodynamic imbalances present in the shock syndromeblood pressure control in certain acute hypotensive states and for intravenous induction of general anesthesia or before administration of other anestheticall of the foregoing comprising gemcitabine; medicinal and pharmaceutical preparations packed in ready to use infusion bags for treatment of cancerpaindiseases related to central nervous systemepilepsyventricular tachycardia or ventricular fibrillationirregular heartbeatanginablood pressure and gynecological disordersall of the foregoing comprising gemcitabine
Class 10
medical apparatusinfusion devices for administering drugs in the nature of ready-to-use infusion bags containing medicinal and pharmaceutical preparations of gemcitabine
Publications
History of USPTO decisions and trademark events.
37 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
11/17/2020
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
10/16/2020
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
10/15/2020
SUPC
STATEMENT OF USE PROCESSING COMPLETE
10/13/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
10/13/2020
IUAF
USE AMENDMENT FILED
09/29/2020
EISU
TEAS STATEMENT OF USE RECEIVED
09/29/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/24/2020
EX2G
SOU EXTENSION 2 GRANTED
04/22/2020
EXT2
SOU EXTENSION 2 FILED
04/22/2020
EEXT
SOU TEAS EXTENSION RECEIVED
04/22/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
10/25/2019
EX1G
SOU EXTENSION 1 GRANTED
10/23/2019
EXT1
SOU EXTENSION 1 FILED
10/23/2019
EEXT
SOU TEAS EXTENSION RECEIVED
10/23/2019
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
04/23/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/26/2019
PUBO
PUBLISHED FOR OPPOSITION
02/26/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/06/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/18/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
01/15/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/15/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
01/15/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/15/2019
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
01/14/2019
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
01/08/2019
ALIE
ASSIGNED TO LIE
12/21/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/29/2018
XAEC
EXAMINER'S AMENDMENT ENTERED
11/29/2018
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/29/2018
GNEA
EXAMINERS AMENDMENT E-MAILED
11/29/2018
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/29/2018
DOCK
ASSIGNED TO EXAMINER
11/27/2018
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
09/27/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/26/2018
NWAP
NEW APPLICATION ENTERED
09/24/2018
Continuous trademark protection
Get notified about every new filing that threatens GEMCITABINE IN 0.9% SODIUM CHLORIDE INJECTION 1,500 MG PER 150 ML (10 MG/ML) or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.